MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Trial Details

NCT ID
NCT04762199
Phase
PHASE1
Sponsor
Emory University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Flt3/MerTK Inhibitor MRX-2843
  • Osimertinib
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Patients must have histologically confirmed metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation including typical and atypi…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Patients in the expansion cohort must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimen…
  • Ability to safely swallow oral medication

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →